Case Study: Immunotherapy in a Young Adult with Atypical Neuroendocrine Tumour

#1918

Introduction: Use of immunotherapy PD-1 antibody has emerged as a novel therapeutic option for treating multiple solid tumors. In the setting of neuroendocrine tumors (NETs), little is known. Currently, trials are underway investigating its use in high-grade NETs, but outcomes remain to be seen

Aim(s): Case report demonstrating the use of monotherapy PD-1 antibody Pembrolizumab in a patient with advanced NET

Materials and methods: A 39-yo male diagnosed 11-years prior with local, atypical thymic carcinoid (Ki-67 of 11%). Failing twice thymectomy, platinum based chemotherapy, mTOR inhibitors, and Lanreotide, referred to our tertiary center for young adults with rare tumours. His chief complaint was dyspnea secondary to significant tumour burden in the mediastinum. He also had multiple bony metastasis. After discussion with the patient, decision was undertaken to start Pembrolizumab monotherapy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kavan P

Authors: Stavrides-Eid M, Soo Rho Y, Barrera I, Kavan P,

Keywords: thymic neuroendocrine tumour, pembrolizumab, atypical carcinoid, NETs,

To read the full abstract, please log into your ENETS Member account.